

**Date:** December 04, 2025

To,  
Sr. General Manager  
Listing Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400 001

**BSE Scrip Code: 544319**

To,  
Sr. General Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**NSE Symbol: SENORES**


**Sub.: Disclosure as required under Regulation 31(1) and 31(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulation, 2011**

In pursuance of Regulation 31(1) and 31(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SAST Regulations”), please find attached disclosure under SAST Regulations for Pledge of 4,00,000 (Four Lakhs) Equity Shares on December 03, 2025 of Senores Pharmaceuticals Limited.

This is for your information and records.

Thanking You.

**Yours Faithfully,**  
**For Renosen Pharmaceuticals Private Limited**

  
**Swapnil Jatinbhai Shah**  
Director  
DIN: 05259821



CC:  
**Company Secretary**  
Senores Pharmaceuticals Limited  
1101 to 1103, 11<sup>th</sup> Floor, South Tower, One 42,  
Opp. Jayantilal Park, Ambali Bopal Road,  
Ahmedabad -380054

**Enclosure:** As above

**Renosen Pharmaceuticals Private Limited**

(Formerly known as Senores Lifesciences Pvt. Ltd.)

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India.  
P: +91 79 2999 9857 | E: info@senorespharma.com | CIN NO: U51909GJ2019PTC108258

**Disclosure by the Promoter(s) to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/ release of encumbrance, in terms of Regulation 31(1) and 31(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

|    |                                                                                           |                                                                          |
|----|-------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| 1. | Name of the Target Company                                                                | Senores Pharmaceuticals Limited                                          |
| 2. | Names of the stock exchanges where the shares of the target company are listed            | BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") |
| 3. | Date of reporting                                                                         | December 04,2025                                                         |
| 4. | Name of the Promoter or PAC on whose shares encumbrance has been created/released/invoked | Renosen Pharmaceuticals Private Limited                                  |


**5. Details of encumbrance:**


[illegible]



|                               |           |        |   |   |  |  |  |  |  |  |  |  |  |
|-------------------------------|-----------|--------|---|---|--|--|--|--|--|--|--|--|--|
| Shantaben Babulal Sanghvi     | 3,28,569  | 0.7134 | - | - |  |  |  |  |  |  |  |  |  |
| Remus Pharmaceuticals Limited | 32,61,744 | 7.0825 | - | - |  |  |  |  |  |  |  |  |  |

**For and on behalf of Renosen Pharmaceuticals Private Limited**

  
**Name:** Swapnil Jatinbhai Shah  
**Designation:** Director  
**DIN:** 05259821



**Date:** 04/12/2025

**Place:** Ahmedabad

*\*The names of all the promoters, their shareholding in the target company and their pledged shareholding as on the reporting date should appear in the table irrespective of whether they are reporting on the date of event or not.*

*\*\* For example, for the purpose of collateral for loans taken by the company, personal borrowing, third party pledge, etc.*

*\*\*\*This would include name of both the lender and the trustee who may hold shares directly or on behalf of the lender.*